EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of Statins and Renin–Angiotensin–Aldosterone System Inhibitors on IL-6 Levels in COVID-19 Patients

Laura Pereckaite iD, Neringa Vaguliene, Agne Vitkauskaite, Astra Vitkauskiene, Daiva Urboniene iD

Journal of Clinical Medicine · 26.10.2024 · 13 (21) · 6414

DOI: 10.3390/jcm13216414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 26.10.2024. Verfasst von Laura Pereckaite und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, Eiveniu Str. 2, LT-50161 Kaunas, L…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Severe clinical course and mortality from COVID-19 are mostly associated with increased concentrations of IL-6 and IL-10. Findings from clinical trials suggest that both statins and renin–angiotensin–aldosterone system inhibitors (RAASI) might have the potential to reduce unfavorable outcomes in patients with COVID-19. The aim of this study was to evaluate the effect of statins and RAASI on the cytokine concentrations in COVID-19 patients.

Methods

SARS-CoV-2 infected patients were enrolled in this study, and demographic, clinical, and routine laboratory data were evaluated. Plasma cytokine levels were measured by multiplex assay.

Results

COVID-19 patients with chronic cardiovascular diseases (CVD) had significantly lower median plasma IL-6 levels than COVID-19 patients with no co-morbidities (26 vs. 53 pg/mL, p = 0.021). COVID-19 patients with CVD who were taking statins had significantly lower median concentrations of IL-6 (21 vs. 44 pg/mL, p = 0.027), TNFα (21 vs. 39.5 pg/mL, p = 0.036), and IL-10 (19 vs. 25.5 pg/mL, p = 0.025) compared to COVID-19 patients with no CVD. In a binary logistic regression model, IL-6 was a significant variable, with an odds ratio value of 0.961 (95% CI 0.929–0.995). Regarding RAASI, only plasma IL-6 (22 vs. 44 pg/mL, p = 0.012) levels were found to be significantly lower in COVID-19 patients with CVD consuming these medications compared to patients who did not have any CVD.

Conclusions

COVID-19 patients who had chronic cardiovascular co-morbidities and who were administered statins or RAASI had significantly lower concentrations of IL-6 than COVID-19 patients who did not have any co-morbidities. These findings suggest that the use of statins or RAASI may be of value in COVID-19 patients.

Schlagwörter

Stichwörter der Autor:innen

COVID-19IL-6SARS-CoV-2cardiovascular co-morbiditiesmedicationrenin–angiotensin–aldosterone system inhibitorsstatins

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, Eiveniu Str. 2, LT-50161 Kaunas, Lithuania.
  • Department of Pulmonology, Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, Eiveniu Str. 2, LT-50161 Kaunas, Lithuania.
  • Department of Obstetrics and Gynecology, Faculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, Eiveniu Str. 2, LT-50161 Kaunas, Lithuania.

ORCID-Profile: Laura Pereckaite, Daiva Urboniene

Zitieren

APA

Pereckaite, L., Vaguliene, N., Vitkauskaite, A., Vitkauskiene, A., & Urboniene, D. (2024). Effect of Statins and Renin–Angiotensin–Aldosterone System Inhibitors on IL-6 Levels in COVID-19 Patients. Journal of Clinical Medicine, 13(21), 6414. https://doi.org/10.3390/jcm13216414

Vancouver

Pereckaite L, Vaguliene N, Vitkauskaite A, Vitkauskiene A, Urboniene D. Effect of Statins and Renin–Angiotensin–Aldosterone System Inhibitors on IL-6 Levels in COVID-19 Patients. Journal of Clinical Medicine. 2024;13(21):6414. doi:10.3390/jcm13216414

BibTeX
@article{Pereckaite2024,
  author = {Pereckaite, Laura and Vaguliene, Neringa and Vitkauskaite, Agne and Vitkauskiene, Astra and Urboniene, Daiva},
  title = {Effect of Statins and Renin–Angiotensin–Aldosterone System Inhibitors on IL-6 Levels in COVID-19 Patients},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {21},
  pages = {6414},
  doi = {10.3390/jcm13216414}
}
Kostenlos starten →